EGFR and lung adenocarcinoma: However, for 75 advanced lung adenocarcinoma patients receiving EGFR tyrosine kinase inhibitor (EGFR‐TKI) treatment, there was no significant correlation between PHLPP2 protein expression and any clinicopathological characteristics reported by Xie et al. 34 The inconsistent results might be due to discrepancies in different techniques of detection, scoring methods of PHLPP2 expression, unequal cutoff points, sample size, and the treatment of EGFR‐TKI for patients after surgery between these two studies.